Curis Provides Updated Trial Data Of Blood Cancer Treatment
WASHINGTON (dpa-AFX) - Curis Inc. (CRIS), a biotechnology company focused on cancer treatment, Wednesday announced updated data from its ongoing phase 1/2 study of CA-4948 in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.
According to data from a cutoff date of February 8 in 15 patients, 8 MDS and 7 AML patients, bone marrow blast reductions were observed at all tested doses in 8 of 9 evaluable patients. Four objective responses were recorded with signs of hematologic recovery.
The company said two abstracts for CA-4948 have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually from June 9-17, 2021.
Curis to Present at 20th Annual Needham Virtual Healthcare Conference
News provided by
Share this article
Share this article
LEXINGTON, Mass., April 6, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 10:15 am ET.
A live webcast of the presentation will be available under Events & Presentations in the Investors section of the Company s website at www.curis.com. A replay of the webcast will be available on the Curis website for approximately 90 days following the event.
Share this article
Share this article
LEXINGTON, Mass., March 16, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2020. 2020 was a transformative year for Curis, as we made significant progress in our mission to develop the next generation of targeted cancer therapies that meaningfully improve and extend the lives of patients. Despite the difficulties and uncertainty brought about by the ongoing coronavirus pandemic, we significantly advanced and expanded each program in our clinical pipeline, headlined by the very encouraging data from our Phase 1 trials of lead asset, CA-4948, presented in December in conjunction with ASH, said James Dentzer, President and Chief Executive Officer of Curis. We look forward to providing additional updates on our IRAK4 program throughout the year, with
Share this article CAMMARATA HONORED BY HEALTHCARE TECHNOLOGY REPORT
LAVAL, QC, March 2, 2021 /PRNewswire/ - Neptune Wellness Solutions Inc. ( Neptune or the Company ) (NASDAQ: NEPT) (TSX: NEPT) President and CEO Michael Cammarata has been named one of the Top 25 Biotech CEOs of 2021 by
The Healthcare Technology Report.
Mr. Cammarata has led Neptune Wellness Solutions Inc., a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, since 2019. I m honored to be acknowledged alongside some of the most revolutionary thought leaders in the biotech industry today, said Michael Cammarata, President and Chief Executive Officer of Neptune Wellness Solutions Inc. This honor would not be possible without the brilliant and resilient Neptune team, whose passion for health and wellness drives us forward and makes life-changing breakthroughs possible even, and especially, when faced with the unprece